Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
2 papers
Research on MDMA for anxiety is promising but still limited. The strongest and most consistent results come from studies of MDMA used with psychotherapy for post‑traumatic stress disorder (PTSD), an anxiety‑related illness. Some smaller studies have also tested MDMA and other psychedelics for other anxiety problems and reported reductions in symptoms, but the number of trials is small. Most studies give MDMA inside a carefully controlled therapy program, and safety looks acceptable in those settings. Still, trials are often small, participants are not very diverse, and scientists do not yet fully understand how MDMA produces its effects or what the long‑term risks are. More research is needed before MDMA could be considered a standard treatment for general anxiety disorders.
This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…
Researchers reviewed the fast-growing interest in psychedelic therapies. They found that even though hundreds of studies are under way, no psychedelic medicine is officially approved for any mental health condition yet. The review explains the kinds of drugs being tested, the conditions people hope to treat, and big challenges such…
